Basisstatistiken
| LEI | 549300C3XPVV86UK2O23 |
| CIK | 1638097 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Entera Bio Ltd.
SEC Filings (Chronological Order)
Auf dieser Seite finden Sie eine vollständige, chronologische Liste der SEC-Einreichungen, mit Ausnahme der Eigentumseinreichungen, die wir an anderer Stelle bereitstellen.
| June 3, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| June 3, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| June 3, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| May 15, 2026 |
19,569,472 Ordinary Shares offered by the Selling Shareholders ENTERA BIO LTD. Filed pursuant to Rule 424(b)(3) Registration No. 333-295710 PROSPECTUS 19,569,472 Ordinary Shares offered by the Selling Shareholders ENTERA BIO LTD. This prospectus relates to the offer and resale from time to time by the selling shareholders identified in this prospectus (the “Selling Shareholders”) of up to 19,569,472 of our ordinary shares, par value of NIS 0.0000769 per share (“ordinary shar |
|
| May 14, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| May 8, 2026 |
ENTERA BIO LTD. CONDENSED CONSOLIDATED BALANCE SHEETS (U.S. dollars in thousands) Exhibit 99.1 Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs EB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis – Phase 3 protocol submitted with FDA feedback expected imminently; incremental data submitted to ENDO2026 and ASBMR EB612, the first oral long-acting PTH peptide replacement tablet f |
|
| May 8, 2026 |
As filed with the Securities and Exchange Commission on May 8, 2026 As filed with the Securities and Exchange Commission on May 8, 2026 Registration No. |
|
| May 8, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2026 Entera Bio Ltd. (Exact Name of Registrant as Specified in Its Charter) Israel 001-38556 Not Applicable (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 8, 2026 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-3 Entera Bio Ltd Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Ordinary shares, par value of NIS 0. |
|
| May 8, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38556 ENTERA BI |
|
| April 3, 2026 |
ORDINARY SHARE PURCHASE WARRANT ENTERA BIO LTD. Exhibit 10.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| April 3, 2026 |
Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 1, 2026, between Entera Bio Ltd., a company organized under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each purchaser, including its successors and permitted assigns, a “Purchaser” and collectively |
|
| April 3, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2026 Entera Bio Ltd. (Exact Name of Registrant as Specified in Its Charter) Israel 001-38556 Not Applicable (State or other jurisdiction of incorporation) (Commission File Nu |
|
| April 3, 2026 |
PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT ENTERA BIO LTD. Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| April 3, 2026 |
Exhibit 10.4 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of April 2, 2026, between Entera Bio Ltd., a company organized under the laws of the State of Israel (the “Company”), and each of the purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the |
|
| March 27, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2026 Entera Bio Ltd. (Exact Name of Registrant as Specified in Its Charter) Israel 001-38556 Not Applicable (State or other jurisdiction of incorporation) (Commission File N |
|
| March 27, 2026 |
ENTERA BIO LTD. 2018 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT Exhibit 10.10 ENTERA BIO LTD. 2018 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT , 2020 Subject to the terms and conditions set forth in this grant letter (the “Grant Letter”) and the award agreement set forth in Exhibit A (the Grant Letter and Exhibit A, collectively this “Agreement”), Entera Bio Ltd., a company organized under the laws of the State of Israel (the “Company”), has gr |
|
| March 27, 2026 |
Exhibit 21.1 Entera Bio Ltd. The following is a list of subsidiaries of Entera Bio Ltd. as of December 31, 2025: SUBSIDIARY STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION Entera Bio Inc. Delaware |
|
| March 27, 2026 |
Exhibit 19.1 ENTERA BIO LTD. SECURITIES TRADING POLICY (Compliance with U.S. Securities Laws and Security Trading) This Securities Trading Policy (this “Policy”) contains the following sections: 1.0 General 2.0 Definitions 3.0 Statement of Policy 4.0 Certain Exceptions 5.0 Special Blackout Periods, Pre-clearance of Trades and Other Procedures 6.0 10b5-1 Plans/Margin Accounts and Pledges/Short Sale |
|
| March 27, 2026 |
Exhibit 10.15 July 16, 2025 Amendment to the Employment Agreement Effective as of April 1, 2025, Appendix A to the Employment Agreement from October 1, 2013 and its amendments shall be amended as follows: 1. Item 1 shall be replaced by the following: 1. Salary The Employee shall be entitled to a gross monthly salary of 42,000 NIS (the "Base Salary"). In consideration for overtime hours the Employe |
|
| March 27, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| March 27, 2026 |
ENTERA BIO LTD. CONSOLIDATED BALANCE SHEETS (U.S. dollars in thousands) Exhibit 99.1 Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates EB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis – FDA Type A endpoint alignment in July 2025, Phase 3 protocol submitted to the FDA with comments expected in early Q2 2026 EB612, the first long-acting oral PTH peptide replacement tablet for patie |
|
| March 4, 2026 |
Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis Phase 3 study designed with total hip BMD primary endpoint assessed at 12 months, rather than at 24 months EB613 single tablet final commercial formulation (Next-Gen EB613) replaces multi-tablet EB613 as Phase 3 candidate, following successful bridging study Topline data anticipated in the second half of 2028, approximately one year earlier than previously expected; Entera commits to a 12-month extension study to run in parallel with potential NDA review TEL AVIV, March 4, 2026 - Entera Bio Ltd. |
|
| March 4, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2026 Entera Bio Ltd. (Exact Name of Registrant as Specified in Its Charter) Israel 001-38556 Not Applicable (State or other jurisdiction of incorporation) (Commission File Nu |
|
| February 9, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2026 Entera Bio Ltd. (Exact Name of Registrant as Specified in Its Charter) Israel 001-38556 Not Applicable (State or other jurisdiction of incorporation) (Commission File |
|
| February 9, 2026 |
Exhibit 99.1 Entera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key Milestones New Chairman Joins Entera’s Board with Senior Global Leadership Experience from Pfizer, Wyeth and Other Leading Biopharma Companies as Entera Advances Multiple Oral Peptide Programs Toward Significant Milestones in 2026 TEL AVIV, February 9, 2026 - Entera Bio Ltd. (NASDAQ: ENTX |
|
| February 4, 2026 |
Exhibit 99.1 OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism This is the third program that successfully combines Entera’s oral peptide N-Tab® platform with OPKO’s advanced protein chemistry capabilities The companies have accelerated this program and aim to file an investigational new drug (IND) application i |
|
| February 4, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2026 Entera Bio Ltd. (Exact Name of Registrant as Specified in Its Charter) Israel 001-38556 Not Applicable (State or other jurisdiction of incorporation) (Commission File |
|
| February 4, 2026 |
Exhibit 10.1 Execution Version AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT by and between ENTERA BIO LTD., OPKO BIOLOGICS LTD., and OPKO HEALTH, INC. TABLE OF CONTENTS Page 1. DEFINITIONS 1 2. LICENSES; EXCLUSIVITY 12 2.1 Licenses 12 2.2 Sublicensing and Subcontracting 12 2.3 Technology Transfer Activities 13 2.4 Exclusivity 14 3. GOVERNANCE 15 3.1 Joint Steering Committee 15 3.2 Subc |
|
| November 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2025 Entera Bio Ltd. (Exact Name of Registrant as Specified in Its Charter) Israel 001-38556 Not Applicable (State or other jurisdiction of incorporation) (Commission Fil |
|
| November 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38556 ENTER |
|
| November 14, 2025 |
ENTERA BIO LTD. CONSOLIDATED BALANCE SHEETS Exhibit 99.1 Entera Bio Announces Third Quarter 2025 Financial Results and Business Updates FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study EB613 Phase 2 Data Demonstrating Consistent Efficacy across Younger Post-Menopausal Women with Osteoporosis and its Impact on Trabecular and Cortical Bone Indices, Highlighted at NAMS and ASBMR Next-Generation EB613 Remains on |
|
| August 8, 2025 |
Exhibit 10.1 AMENDMENT NO. 1 TO SALES AGREEMENT June 5, 2025 Leerink Partners LLC 1301 Avenue of the Americas, 5th Floor New York, New York 10019 Ladies and Gentlemen: Entera Bio Ltd., a company organized under the laws of Israel (the “Company”), and Leerink Partners LLC (the “Agent”) are parties to that certain Sales Agreement dated September 2, 2022 (the “Original Agreement”). All capitalized te |
|
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2025 Entera Bio Ltd. (Exact Name of Registrant as Specified in Its Charter) Israel 001-38556 Not Applicable (State or other jurisdiction of incorporation) (Commission File N |
|
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38556 ENTERA BIO LTD. (Exac |
|
| August 8, 2025 |
Exhibit 99.1 Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates • FDA provides pivotal agreement on EB613 Phase 3 design, confirming Bone Mineral Density (BMD) as primary endpoint and clearing streamlined pathway for first oral anabolic osteoporosis treatment • Significant regulatory and pipeline advancements achieved including FDA waiver of additional safety studies a |
|
| July 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2025 Entera Bio Ltd. (Exact Name of Registrant as Specified in Its Charter) Israel 001-38556 Not Applicable (State or other jurisdiction of incorporation) (Commission File Nu |
|
| July 28, 2025 |
Exhibit 99.1 Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis JERUSALEM, July 28, 2025 (GLOBE NEWSWIRE) - Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and protein replacement therapies, announced today that in a written response to a Type A meeting request, the U.S. Food a |
|
| July 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2025 Entera Bio Ltd. (Exact Name of Registrant as Specified in Its Charter) Israel 001-38556 Not Applicable (State or other jurisdiction of incorporation) (Commission File Nu |
|
| June 6, 2025 |
Up to 30,000,000 Ordinary Shares Filed pursuant to Rule 424(b)(3) Registration No. 333-287676 Prospectus Up to 30,000,000 Ordinary Shares We have entered into a sales agreement (as amended to date, the “Sales Agreement”) with Leerink Partners LLC (“Leerink Partners” or the “sales agent”), dated September 2, 2022, relating to the sale of our ordinary shares, par value NIS 0.0000769 per share (the “ordinary shares”), offered by thi |
|
| June 5, 2025 |
81,7('67$7(6 6(&85,7,(6$1'(;&+$1*(&200,66,21 :$6+,1*721'& )250. |
|
| June 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| June 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| June 4, 2025 |
Entera Bio Ltd. Minrav Building – Fifth Floor Jerusalem, Israel 9112002 June 4, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attention: Jason Drory RE: Entera Bio Ltd. (the “Company”) Registration Statement on Form S-3 (the “Registration Statement”) Filed May 30, 2025 File No. 333-287676 Dear Mr. Drory: The |
|
| June 4, 2025 |
June 4, 2025 Miranda Toledano Chief Executive Officer Entera Bio Ltd. Kiryat Hadassah Minrav Building - Fifth Floor Jerusalem, Israel 9112002 Re: Entera Bio Ltd. Registration Statement on Form S-3 Filed May 30, 2025 File No. 333-287676 Dear Miranda Toledano: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding |
|
| May 30, 2025 |
Form of Subordinated Indenture Exhibit 4.2 Entera Bio Ltd. as the Company and [ ] as Trustee Subordinated Indenture Dated as of [ ], [ ] TABLE OF CONTENTS Page Article 1 Definitions And Incorporation By Reference Section 1.01. Definitions 1 Section 1.02. Other Definitions 4 Section 1.03. Incorporation by Reference of Trust Indenture Act 4 Section 1.04. Rules of Construction 4 Article 2 The Securities Section 2.01. Form and Dati |
|
| May 30, 2025 |
As filed with the Securities and Exchange Commission on May 30, 2025 As filed with the Securities and Exchange Commission on May 30, 2025 Registration No. |
|
| May 30, 2025 |
Calculation of Filing Fee Tables Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Entera Bio Ltd. (Exact name of registrant as specified in its charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule(2) Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary Shares, par valu |
|
| May 30, 2025 |
Exhibit 4.1 Entera Bio Ltd. as the Company and [ ] as Trustee Senior Indenture Dated as of [ ], [ ] TABLE OF CONTENTS Page Article 1 Definitions and Incorporation by Reference Section 1.01. Definitions 1 Section 1.02. Other Definitions 4 Section 1.03. Incorporation by Reference of Trust Indenture Act 4 Section 1.04. Rules of Construction 4 Article 2 The Securities Section 2.01. Form and Dating 5 S |
|
| May 30, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Entera Bio Ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry F |
|
| May 30, 2025 |
As filed with the Securities and Exchange Commission on May 30, 2025 As filed with the Securities and Exchange Commission on May 30, 2025 Registration No. |
|
| May 23, 2025 |
May 23, 2025 Dana Yaacov-Garbeli Chief Financial Officer Entera Bio Ltd. Minrav Building Fifth Floor Jerusalem, Israel 9112002 Re: Entera Bio Ltd. Form 10-K for the fiscal year ended December 31, 2024 File No. 001-38556 Dear Dana Yaacov-Garbeli: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disc |
|
| May 20, 2025 |
May 19, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporate Finance Office of Life Sciences 100 F Street, N. |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| May 9, 2025 |
Exhibit 99.1 Entera Bio Announces First Quarter 2025 Financial Results and Business Updates JERUSALEM, May 9th 2025 –Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for the quarter ended March 31, 2025. “During Q1 2025, Entera continued to generate intrinsic value with progress |
|
| May 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2025 Entera Bio Ltd. (Exact Name of Registrant as Specified in Its Charter) Israel 001-38556 Not Applicable (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38556 ENTERA BIO LTD. (Exa |
|
| May 6, 2025 |
May 6, 2025 Dana Yaacov-Garbeli Chief Financial Officer Entera Bio Ltd. Minrav Building Fifth Floor Jerusalem, Israel 9112002 Re: Entera Bio Ltd. Form 10-K for the fiscal year ended December 31, 2024 File No. 001-38556 Dear Dana Yaacov-Garbeli: We have limited our review of your filing to the financial statements and related disclosures and have the following comment. Please respond to this letter |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| March 28, 2025 |
Entera Bio Ltd. Insider Trading Policy Exhibit 19.1 ENTERA BIO LTD. SECURITIES TRADING POLICY (Compliance with U.S. Securities Laws and Security Trading) This Securities Trading Policy (this “Policy”) contains the following sections: 1.0 General 2.0 Definitions 3.0 Statement of Policy 4.0 Certain Exceptions 5.0 Special Blackout Periods, Pre-clearance of Trades and Other Procedures 6.0 10b5-1 Plans/Margin Accounts and Pledges/Short Sale |
|
| March 28, 2025 |
Exhibit 99.1 Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates JERUSALEM, March 28 2025 –Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, today reported financial results and key business achievements for the year ended December 31, 2024. “2024 was a truly transformational year for Entera. We delivere |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2025 Entera Bio Ltd. (Exact Name of Registrant as Specified in Its Charter) Israel 001-38556 Not Applicable (State or other jurisdiction of incorporation) (Commission File N |
|
| March 28, 2025 |
Exhibit 21.1 Entera Bio Ltd. The following is a list of subsidiaries of Entera Bio Ltd. as of December 31, 2024: STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION SUBSIDIARY Delaware Entera Bio Inc. |
|
| March 17, 2025 |
Exhibit 99.1 OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders MIAMI and JERUSALEM, March 17, 2025 – OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX) , a leader in the development of oral peptides and proteins replacement therapies, entered into a collaboration and |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2025 Entera Bio Ltd. (Exact Name of Registrant as Specified in Its Charter) Israel 001-38556 Not Applicable (State or other jurisdiction of incorporation) (Commission File N |
|
| March 17, 2025 |
Exhibit 10.1 COLLABORATION AND LICENSE AGREEMENT by and between ENTERA BIO LTD., OPKO BIOLOGICS LTD., and OPKO HEALTH, INC. i TABLE OF CONTENTS 1. DEFINITIONS 1 2. LICENSES; EXCLUSIVITY 11 2.1 Licenses 11 2.2 Sublicensing and Subcontracting 11 2.3 Technology Transfer Activities 11 2.4 Exclusivity 12 3. GOVERNANCE 13 3.1 Joint Steering Committee 13 3.2 Subcommittees 14 3.3 Alliance Managers 15 4. R |
|
| January 10, 2025 |
Up to 30,000,000 Ordinary Shares Filed pursuant to Rule 424(b)(5) Registration No. 333-265286 Supplement No. 1 dated January 10, 2025 to Prospectus Supplement dated September 2, 2022 (to Prospectus dated June 9, 2022) Up to 30,000,000 Ordinary Shares This supplement no. 1 (this “Supplement”) supplements certain information contained in the prospectus supplement dated September 2, 2022 (as amended by this Supplement, the “prospect |
|
| January 10, 2025 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 Entera Bio Ltd. (Exact Name of Registrant as Specified in Its Charter) Israel 001-38556 Not Applicable (State or other jurisdiction of incorporation) (Commission File |
|
| January 6, 2025 |
JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) EXHIBIT 99.1 JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned |
|
| December 20, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2024 Entera Bio Ltd. (Exact Name of Registrant as Specified in Its Charter) Israel 001-38556 Not Applicable (State or other jurisdiction of incorporation) |
|
| November 20, 2024 |
ENTX / Entera Bio Ltd. / Knoll Capital Management, LLC - SC 13G/A Passive Investment SC 13G/A 1 tm2429021d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. 3)* Entera Bio Ltd. (Name of Issuer) Ordinary Shares Nominal value of NIS 0.0000769 per share (Title o |
|
| November 8, 2024 |
GREGE UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38556 ENTERA BIO |
|
| November 8, 2024 |
Exhibit 99.1 Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates JERUSALEM – November 8, 2024 (GLOBE NEWSWIRE) - Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of oral peptides and small therapeutic proteins, today reported financial results and key business updates for the quarter ended September 30, 2024. “The third quarter of 2024 |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2024 Entera Bio Ltd. (Exact Name of Registrant as Specified in Its Charter) Israel 001-38556 Not Applicable (State or other jurisdiction of incorporation) (Commission File |
|
| August 20, 2024 |
ENTX / Entera Bio Ltd. / CENTILLION FUND INC. - AMENDMENT NO. 6 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 6)* ENTERA BIO LTD. (Name of Issuer) Ordinary Shares, nominal value of NIS 0.0000769 per share (Title of Class of Securities) M40527109 (CUSIP Number) July 19, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to design |
|
| August 9, 2024 |
As filed with the Securities and Exchange Commission on August 9, 2024 S-8 1 zk2431788.htm S-8 As filed with the Securities and Exchange Commission on August 9, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ——————————— Entera Bio Ltd. (Exact name of registrant as specified in its charter) State of Israel Not Applicable (State or other jurisdiction of |
|
| August 9, 2024 |
Calculation of Filing Fee Tables EX-FILING FEES 4 exhibit107.htm EXHIBIT 107 Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Entera Bio Ltd. (Exact name of registrant as specified in its charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule(2) Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Regis |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2024 Entera Bio Ltd. (Exact Name of Registrant as Specified in Its Charter) Israel 001-38556 Not Applicable (State or other jurisdiction of incorporation) (Commission File N |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38556 ENTERA BIO LTD. (Exac |
|
| August 9, 2024 |
Exhibit 99.1 Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates JERUSALEM – August 9th, 2024 (GLOBE NEWSWIRE) - Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today reported financial results and key business updates for the quarter ended June 30, 2024. "We continue to deli |
|
| August 2, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2024 Entera Bio Ltd. (Exact Name of Registrant as Specified in Its Charter) Israel 001-38556 Not Applicable (State or other jurisdiction of incorporation) (Commission File Nu |
|
| June 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| June 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| June 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ց ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR տտ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| May 10, 2024 |
Exhibit 99.1 Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates JERUSALEM – May 10th, 2024 (GLOBE NEWSWIRE) - Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today reported financial results and key business updates for the quarter ended March 31, 2024. “Entera is off to a s |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38556 ENTERA BIO LTD. (Exa |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2024 Entera Bio Ltd. (Exact Name of Registrant as Specified in Its Charter) Israel 001-38556 00-0000000 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| March 8, 2024 |
Calculation of Filing Fee Tables Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Entera Bio Ltd. (Exact name of registrant as specified in its charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule(2) Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary Shares, par valu |
|
| March 8, 2024 |
As filed with the Securities and Exchange Commission on March 8, 2024 As filed with the Securities and Exchange Commission on March 8, 2024 Registration No. |
|
| March 8, 2024 |
Exhibit 10.12 Personal Employment Agreement This Personal Employment Agreement (this “Agreement”), is entered into at Hadassah, J-m on 8 June 2014 this effective as of March, 2014, by and between: Entera Bio Ltd. of Kiryat Hadassah, Minrav Building – Fifth Floor, POB 12117, Jerusalem 91220, Israel (the “Company”); and Hillel Galitzer (ID No. 015346109) of Slav 43, Yad Binyamin (the “Executive”). W |
|
| March 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2024 Entera Bio Ltd. (Exact Name of Registrant as Specified in Its Charter) Israel 001-38556 00-0000000 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 8, 2024 |
Exhibit 10.10 AMENDMENT TO EMPLOYMENT AGREEMENT This Amendment to Employment Agreement (“Amendment”) is made as of January 31, 2024 by and between Entera Bio Ltd. an Israeli company (the “Company”) and Miranda Toledano (the “Employee”, and together with the Company, the “Parties”). WHEREAS: A. The Company and the Employee entered into a personal employment agreement, as amended (the “Agreement”), |
|
| March 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| March 8, 2024 |
Exhibit 21.1 Entera Bio Ltd. The following is a list of subsidiaries of Entera Bio Ltd. as of December 31, 2023: STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION SUBSIDIARY Delaware Entera Bio Inc. |
|
| March 8, 2024 |
Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates Exhibit 99.1 Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates JERUSALEM – March 8, 2024 (GLOBE NEWSWIRE) - Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, today reported financial results and key business updates for the fourth quarter and year ended December 31, 2023. “2023 was an inflection p |
|
| March 8, 2024 |
Entera Bio Ltd. Executive Officer Clawback Policy, effective as of November 30, 2023 Exhibit 97 Entera Bio Ltd. Executive Officer Clawback Policy Approved by the Board of Directors on November 30, 2023 (the “Adoption Date”) I. Purpose This Executive Officer Clawback Policy describes the circumstances under which Covered Persons of Entera Bio Ltd., a company organized under the laws of the State of Israel, and any of its direct or indirect subsidiaries (collectively, the “Company”) |
|
| March 8, 2024 |
Exhibit 10.11 CONSULTANCY AGREEMENT This Consultancy Agreement ("Agreement") is entered into effective as of June 2, 2019, by and between Entera Bio Ltd., an Israeli company I.D. No. 514330604 ("Company"), and A2Z Finance Ltd., a company organized under the laws of the State of Israel ("Consultant"). WHEREAS, the Consultant agrees to perform the Services for the interim period until the engagement |
|
| March 4, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2024 Entera Bio Ltd. (Exact Name of Registrant as Specified in Its Charter) Israel 001-38556 00-0000000 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 4, 2024 |
Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement Exhibit 99.1 Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement JERUSALEM – March 4, 2024 (GLOBE NEWSWIRE) - Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, announced today that it received notice from The NASDAQ Stock Market LLC (NASDAQ) on March 1, 2024, informing the Company that it has regained complianc |
|
| February 15, 2024 |
16,500,894 Ordinary Shares offered by the Selling Shareholders ENTERA BIO LTD. Filed pursuant to Rule 424(b)(3) Registration No. 333-276844 PROSPECTUS 16,500,894 Ordinary Shares offered by the Selling Shareholders ENTERA BIO LTD. This prospectus relates to the offer and resale from time to time by the selling shareholders identified in this prospectus (the “Selling Shareholders”) of up to 16,500,894 shares of our ordinary shares, par value of NIS 0.0000769 per share (“ordina |
|
| February 14, 2024 |
As filed with the Securities and Exchange Commission on February 14, 2024 As filed with the Securities and Exchange Commission on February 14, 2024 Registration No. |
|
| February 14, 2024 |
Entera Bio Ltd. Minrav Building – Fifth Floor Jerusalem, Israel 9112002 February 14, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attention: Doris Stacey Gama RE: Entera Bio Ltd. (the “Company”) Registration Statement on Form S-3, as amended (the “Registration Statement”) Filed February 2, 2024 File No. 333- |
|
| February 2, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Entera Bio Ltd. (Exact name of registrant as specified in its charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Fees to Be Paid |
|
| February 2, 2024 |
As filed with the Securities and Exchange Commission on February 2, 2024 As filed with the Securities and Exchange Commission on February 2, 2024 Registration No. |
|
| February 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2024 Entera Bio Ltd. (Exact Name of Registrant as Specified in Its Charter) Israel 001-38556 00-0000000 (State or other jurisdiction of incorporation) (Commission File Num |
|
| January 16, 2024 |
ENTX / Entera Bio Ltd. / Knoll Capital Management, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. 2)* Entera Bio Ltd. (Name of Issuer) Ordinary Shares Nominal value of NIS 0.0000769 per share (Title of Class of Securities) M40527109 (CUSIP Nu |
|
| January 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2024 Entera Bio Ltd. (Exact Name of Registrant as Specified in Its Charter) Israel 001-38556 00-0000000 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| December 26, 2023 |
Exhibit 10.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| December 26, 2023 |
Exhibit 10.5 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of December [ ], 2023, between Entera Bio Ltd., a company organized under the laws of the State of Israel (the “Company”), and each of the purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to |
|
| December 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2023 Entera Bio Ltd. (Exact Name of Registrant as Specified in Its Charter) Israel 001-38556 00-0000000 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| December 26, 2023 |
Exhibit 10.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| December 26, 2023 |
Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| December 26, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 20, 2023, between Entera Bio Ltd., a company organized under the laws of the State of Israel (“the “Company”), and each purchaser identified on the signature pages hereto (each purchaser, including its successors and permitted assigns, a “Purchaser” and collectively, the “Purcha |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 Entera Bio Ltd. (Exact Name of Registrant as Specified in Its Charter) Israel 001-38556 00-0000000 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 14, 2023 |
Exhibit 99.1 Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development JERUSALEM – November 14th, 2023 (GLOBE NEWSWIRE) - Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today report |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38556 ENTERA BIO LTD. |
|
| September 13, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2023 Entera Bio Ltd. (Exact Name of Registrant as Specified in Its Charter) Israel 001-38556 00-0000000 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ց ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR տտ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| August 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2023 Entera Bio Ltd. (Exact Name of Registrant as Specified in Its Charter) Israel 001-38556 00-0000000 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 11, 2023 |
Entera Bio Announces Q2 2023 Financial Results and Corporate Updates Exhibit 99.1 Entera Bio Announces Q2 2023 Financial Results and Corporate Updates JERUSALEM – August 11, 2023 (GLOBE NEWSWIRE) - Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today reported corporate updates and financial results for the second quarter ended June 30, 2023. “In the last year, we have su |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38556 ENTERA BIO LTD. (Exac |
|
| July 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| June 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2023 Entera Bio Ltd. (Exact Name of Registrant as Specified in Its Charter) Israel 001-38556 00-0000000 (State or other jurisdiction of incorporation) (Commission File Number |
|
| June 29, 2023 |
Entxw-form25 |
|
| June 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2023 Entera Bio Ltd. (Exact Name of Registrant as Specified in Its Charter) Israel 001-38556 00-0000000 (State or other jurisdiction of incorporation) (Commission File Number |
|
| June 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| June 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2023 Entera Bio Ltd. (Exact Name of Registrant as Specified in Its Charter) Israel 001-38556 00-0000000 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 2, 2023 |
As filed with the Securities and Exchange Commission on June 2, 2023 As filed with the Securities and Exchange Commission on June 2, 2023 Registration No. |
|
| June 2, 2023 |
Calculation of Filing Fee Tables Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Entera Bio Ltd. (Exact name of registrant as specified in its charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule(2) Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary Shares, par valu |
|
| May 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38556 ENTERA BIO LTD. (Exa |
|
| May 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2023 Entera Bio Ltd. (Exact Name of Registrant as Specified in Its Charter) Israel 001-38556 00-0000000 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 5, 2023 |
Exhibit 99.1 Entera Bio Announces Q1 2023 Financial Results and Corporate Updates JERUSALEM – May 5th, 2023 (GLOBE NEWSWIRE) - Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today reported corporate updates and financial results for the first quarter ended March 31, 2023. “Our primary objectives for 202 |
|
| March 31, 2023 |
Exhibit 10.15 Personal Employment Agreement This Personal Employment Agreement (this “Agreement”), is entered into at Hadassah, J-m on 8 June 2014 this effective as of March, 2014, by and between: Entera Bio Ltd. of Kiryat Hadassah, Minrav Building – Fifth Floor, POB 12117, Jerusalem 91220, Israel (the “Company”); and Hillel Galitzer (ID No. 015346109) of Slav 43, Yad Binyamin (the “Executive”). W |
|
| March 31, 2023 |
Exhibit 10.14 CONSULTANCY AGREEMENT This Consultancy Agreement ("Agreement") is entered into effective as of June 2, 2019, by and between Entera Bio Ltd., an Israeli company I.D. No. 514330604 ("Company"), and A2Z Finance Ltd., a company organized under the laws of the State of Israel ("Consultant"). WHEREAS, the Consultant agrees to perform the Services for the interim period until the engagement |
|
| March 31, 2023 |
Exhibit 21.1 Entera Bio Ltd. The following is a list of subsidiaries of Entera Bio Ltd. as of December 31, 2022: SUBSIDIARY STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION Entera Bio Inc. Delaware |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2023 Entera Bio Ltd. (Exact Name of Registrant as Specified in Its Charter) Israel 001-38556 00-0000000 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| March 31, 2023 |
Exhibit 99.1 Entera Bio Provides 2022 Corporate Milestones and Financial Results for the Year Ended December 31, 2022 JERUSALEM – March 31, 2023 (GLOBE NEWSWIRE) - Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced a summary of 2022 corporate achievements and financial results for the year e |
|
| March 31, 2023 |
Report of Independent Registered Public Accounting Firm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| February 14, 2023 |
ENTX / Entera Bio Ltd / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm236221d9sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Entera Bio Ltd. (Name of Issuer) Ordinary Shares Nominal value of NIS 0.0000769 per share (Title of Class of Securities) M40527109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this St |
|
| November 23, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2022 Entera Bio Ltd. (Exact Name of Registrant as Specified in Its Charter) Israel 001-38556 00-0000000 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 18, 2022 |
ENTX / Entera Bio Ltd / CENTILLION FUND INC. - AMENDMENT NO. 4 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* ENTERA BIO LTD. (Name of Issuer) Ordinary Shares, nominal value of NIS 0.0000769 per share (Title of Class of Securities) M40527109 (CUSIP Number) August 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to design |
|
| November 18, 2022 |
ENTX / Entera Bio Ltd / CENTILLION FUND INC. - AMENDMENT NO. 5 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* ENTERA BIO LTD. (Name of Issuer) Ordinary Shares, nominal value of NIS 0.0000769 per share (Title of Class of Securities) M40527109 (CUSIP Number) August 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desi |
|
| November 18, 2022 |
ENTX / Entera Bio Ltd / CENTILLION FUND INC. - AMENDMENT NO. 4 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* ENTERA BIO LTD. (Name of Issuer) Ordinary Shares, nominal value of NIS 0.0000769 per share (Title of Class of Securities) M40527109 (CUSIP Number) August 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to design |
|
| November 10, 2022 |
Exhibit 99.1 Entera Bio Provides Corporate Updates and Financial Results for the Third Quarter of 2022 JERUSALEM ? November 10, 2022 (GLOBE NEWSWIRE) - Entera Bio Ltd. (NASDAQ: ENTX), (?Entera? or the ?Company?) a leader in the development of orally delivered peptides and therapeutic proteins, today announced its financial results for the third quarter of 2022 and provided the following corporate |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 Entera Bio Ltd. (Exact Name of Registrant as Specified in Its Charter) Israel 001-38556 00-0000000 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 10, 2022 |
ENTX / Entera Bio Ltd / CENTILLION FUND INC. - AMENDMENT NO. 3 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* ENTERA BIO LTD. (Name of Issuer) Ordinary Shares, nominal value of NIS 0.0000769 per share (Title of Class of Securities) M40527109 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desi |
|
| November 10, 2022 |
p UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38556 ENTERA BIO LTD |
|
| October 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 6, 2022 Entera Bio Ltd. (Exact Name of Registrant as Specified in Its Charter) Israel 001-38556 00-0000000 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| September 9, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2022 Entera Bio Ltd. (Exact Name of Registrant as Specified in Its Charter) Israel 001-38556 00-0000000 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| September 2, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2022 Entera Bio Ltd. (Exact Name of Registrant as Specified in Its Charter) Israel 001-38556 00-0000000 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| September 2, 2022 |
Up to 5,000,000 Ordinary Shares Filed pursuant to Rule 424(b)(5) Registration No. 333-265286 Prospectus Supplement (to Prospectus dated June 9, 2022) Up to 5,000,000 Ordinary Shares We have entered into a sales agreement (the ?Sales Agreement?) with SVB Securities LLC (?SVB Securities? or the ?sales agent?), dated September 2, 2022, relating to the sale of our ordinary shares, par value NIS 0.0000769 per share (the ?ordinary sha |
|
| September 2, 2022 |
Exhibit 10.1 ENTERA BIO LTD. Ordinary Shares (par value NIS 0.0000769 per share) SALES AGREEMENT September 2, 2022 SVB SECURITIES LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: Entera Bio Ltd., a company organized under the laws of the State of Israel (the ?Company?), confirms its agreement (this ?Agreement?) with SVB Securities LLC (the ?Agent?), as fol |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 Entera Bio Ltd. (Exact Name of Registrant as Specified in Its Charter) Israel 001-38556 00-0000000 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 11, 2022 |
p UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38556 ENTERA BIO LTD. (Ex |
|
| August 11, 2022 |
Exhibit 99.1 Entera Bio Provides Business Highlights and Financial Results for the Second Quarter 2022 JERUSALEM ? August 11, 2022 (GLOBE NEWSWIRE) - Entera Bio Ltd. (NASDAQ: ENTX), (?Entera? or the ?Company?) a leader in the development of orally delivered peptides and therapeutic proteins, today announced its financial and operating results for the quarter ended June 30, 2022. ?We have reset our |
|
| August 1, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2022 Entera Bio Ltd. (Exact Name of Registrant as Specified in Its Charter) Israel 001-38556 00-0000000 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 1, 2022 |
Exhibit 99.1 Entera Bio Corporate PresentationAugust 2022 Disclaimer Various statements in this presentation are ?forward-looking statements? within the meaning of the Private Securities Litigation Reform Act of 1995. All statements (other than statements of historical facts) in this presentation regarding our prospects, plans, financial position, business strategy and expected financial and opera |
|
| July 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| July 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| July 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2022 Entera Bio Ltd. (Exact Name of Registrant as Specified in Its Charter) Israel 001-38556 00-0000000 (State or other jurisdiction of incorporation) (Commission File Number |
|
| July 18, 2022 |
Exhibit 10.1 To: Miranda Toledano July 15, 2022 Amended and Restated Employment Agreement Dear Miranda, You have been employed by Entera Bio Ltd. (the "Company"), an Israeli company, which registered place of business is located at Kiryat Hadassah, Minrav Building ? 5th Floor, Jerusalem, Israel, Israel, as of May 16, 2022 (the "Original Commencement Date"), in accordance with an employment agreeme |
|
| July 18, 2022 |
Exhibit 10.2 Execution Version July 13, 2022 Spiros Jamas 24 Gibson St. Cambridge, MA 02138 Tel +1-617-605-9650 RE: Separation Agreement and General Release Dear Spiros: The purpose of this separation agreement (the ?Separation Agreement?) is to memorialize the terms and conditions of the termination of your employment with Entera Bio, Inc. (the ?Company?) and its subsidiaries, the Company?s paren |
|
| June 17, 2022 |
Exhibit 10.1 MUTUAL SEPARATION AGREEMENT This Mutual Separation Agreement (the ?Agreement?) is made and entered on June 15, 2022 (the ?Effective Date?) by and between Entera Bio Ltd., a company registered in Israel under number 514330604 of Hi-Tech Park 2/5 Givat-Ram, Jerusalem (the "Company") and Phillip Schwartz, ID No. 343880345 of David Alro'i 5(aleph) 35, Jerusalem (the ?Executive?). The Comp |
|
| June 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2022 Entera Bio Ltd. (Exact Name of Registrant as Specified in Its Charter) Israel 001-38556 00-0000000 (State or other jurisdiction of incorporation) (Commission File Number |
|
| June 10, 2022 |
Up to 5,000,000 Ordinary Shares Filed pursuant to Rule 424(b)(3) Registration No. 333-265286 Prospectus Up to 5,000,000 Ordinary Shares We have entered into an amended and restated sales agreement (the ?Sales Agreement?) with B. Riley Securities, Inc. (?B. Riley Securities? or the ?sales agent?), dated May 27, 2022, relating to the sale of our ordinary shares, par value NIS 0.0000769 per share (the ?ordinary shares?), offered by |
|
| June 10, 2022 |
3,763,740 Ordinary Shares offered by the Selling Shareholders ENTERA BIO LTD. Filed pursuant to Rule 424(b)(3) Registration No. 333-265291 PROSPECTUS 3,763,740 Ordinary Shares offered by the Selling Shareholders ENTERA BIO LTD. The selling shareholders named in this prospectus (collectively, the ?Selling Shareholders?) may offer and sell up to 3,763,740 of our ordinary shares, par value of NIS 0.0000769 (?ordinary shares?), from time to time in amounts, at prices and on ter |
|
| June 7, 2022 |
Entera Bio Ltd. Minrav Building ? Fifth Floor Jerusalem, Israel 9112002 June 7, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attention: Michael Davis RE: Entera Bio Ltd. (the ?Company?) Registration Statement on Form S-3 (the ?Registration Statement?) Filed May 27, 2022 File No. 333-265286 Dear Mr. Davis: Th |
|
| June 7, 2022 |
Entera Bio Ltd. Minrav Building ? Fifth Floor Jerusalem, Israel 9112002 June 7, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attention: Michael Davis RE: Entera Bio Ltd. (the ?Company?) Registration Statement on Form S-3 (the ?Registration Statement?) Filed May 27, 2022 File No. 333-265291 Dear Mr. Davis: Th |
|
| June 2, 2022 |
United States securities and exchange commission logo June 1, 2022 Spiros Jamas Chief Executive Officer Entera Bio Ltd. |
|
| June 2, 2022 |
United States securities and exchange commission logo June 1, 2022 Spiros Jamas Chief Executive Officer Entera Bio Ltd. |
|
| May 27, 2022 |
Form of Subordinated Indenture Exhibit 4.2 Entera Bio Ltd. as the Company and [ ] as Trustee Subordinated Indenture Dated as of [ ], [ ] TABLE OF CONTENTS Page Article 1 Definitions And Incorporation By Reference Section 1.01. Definitions 1 Section 1.02. Other Definitions 4 Section 1.03. Incorporation by Reference of Trust Indenture Act 4 Section 1.04. Rules of Construction 4 Article 2 The Securities Section 2.01. Form and Dati |
|
| May 27, 2022 |
As filed with the Securities and Exchange Commission on May 27, 2022 As filed with the Securities and Exchange Commission on May 27, 2022 Registration No. |
|
| May 27, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Entera Bio Ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry F |
|
| May 27, 2022 |
Exhibit 1.2 ENTERA BIO LTD. Ordinary Shares (par value NIS 0.0000769 per share) Amended and Restated At Market Issuance Sales Agreement May 27, 2022 B. Riley Securities, Inc. 299 Park Avenue, 21st Floor New York, NY 10171 Ladies and Gentlemen: Entera Bio Ltd., an Israeli company (the ?Company?) and B. Riley Securities, Inc. (the ?Agent?) are parties to that certain At Market Issuance Sales Agreeme |
|
| May 27, 2022 |
As filed with the Securities and Exchange Commission on May 27, 2022 S-3 1 zk2227914.htm S-3 As filed with the Securities and Exchange Commission on May 27, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ENTERA BIO LTD. (Exact name of registrant as specified in its charter) State of Israel (State or other jurisdiction of incorporation or organization |
|
| May 27, 2022 |
Exhibit 4.1 Entera Bio Ltd. as the Company and [ ] as Trustee Senior Indenture Dated as of [ ], [ ] TABLE OF CONTENTS Page Article 1 Definitions and Incorporation by Reference Section 1.01. Definitions 1 Section 1.02. Other Definitions 4 Section 1.03. Incorporation by Reference of Trust Indenture Act 4 Section 1.04. Rules of Construction 4 Article 2 The Securities Section 2.01. Form and Dating 5 S |
|
| May 27, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Entera Bio Ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee |
|
| May 27, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2022 Entera Bio Ltd. (Exact Name of Registrant as Specified in Its Charter) Israel 001-38556 00-0000000 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 27, 2022 |
Exhibit 10.1 ENTERA BIO LTD. Ordinary Shares (par value NIS 0.0000769 per share) Amended and Restated At Market Issuance Sales Agreement May 27, 2022 B. Riley Securities, Inc. 299 Park Avenue, 21st Floor New York, NY 10171 Ladies and Gentlemen: Entera Bio Ltd., an Israeli company (the ?Company?) and B. Riley Securities, Inc. (the ?Agent?) are parties to that certain At Market Issuance Sales Agreem |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2022 Entera Bio Ltd. (Exact Name of Registrant as Specified in Its Charter) Israel 001-38556 00-0000000 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 16, 2022 |
Exhibit 10.1 To: Miranda Toledano May 15, 2022 Employment Agreement Dear Miranda, We are pleased to extend you this offer of employment in Entera Bio Ltd., an Israeli company, Kiryat Hadassah, Minrav Building ? 5th Floor, Jerusalem, Israel ("Company"), which if you accept by countersigning below, will govern your employment with the Company ("Employment Agreement"). 1. Duties, Obligations and Cons |
|
| May 12, 2022 |
Exhibit 99.1 Entera Bio Reports First Quarter 2022 Financial Results and Business Highlights ? Registrational study design for lead clinical asset, EB613, as the first oral PTH anabolic to treat post-menopausal women at high risk of osteoporosis, is underway BOSTON and JERUSALEM ? May 12, 2022 (GLOBE NEWSWIRE) - Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38556 ENTERA BIO LTD. (Exa |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 Entera Bio Ltd. (Exact Name of Registrant as Specified in Its Charter) Israel 001-38556 00-0000000 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A (Amendment No. |
|
| March 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| March 8, 2022 |
Exhibit 21.1 Entera Bio Ltd. The following is a list of subsidiaries of Entera Bio Ltd. as of December 31, 2021: STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION SUBSIDIARY Delaware Entera Bio Inc. |
|
| March 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2022 Entera Bio Ltd. (Exact Name of Registrant as Specified in Its Charter) Israel 001-38556 00-0000000 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 8, 2022 |
Exhibit 99.1 Entera Bio Reports Financial Results for the Year Ended December 31, 2021 — EB613 expected to commence pivotal Phase 3 Osteoporosis trial in 2022 — New EB612 formulation for Hypoparathyroidism trial planned in 2022 — — Oral delivery technology platform advances with more indications, inventions, patents, and collaborations — ‒ Company to host conference call and webcast today at 8:30 |
|
| February 14, 2022 |
ENTX / Entera Bio Ltd / Capital Point Ltd. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* Entera Bio Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.0000769 per share (Title of Class of Securities) M40527109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| November 10, 2021 |
Exhibit 99.1 ENTERA BIO LTD. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) AS OF SEPTEMBER 30, 2021 ENTERA BIO LTD. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) AS OF SEPTEMBER 30, 2021 TABLE OF CONTENTS Page CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) - U.S DOLLARS IN THOUSANDS ($): Condensed consolidated statements of financial position F-2 Conden |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 Commission file number: 001-38556 ENTERA BIO LTD. (Exact Name of Registrant as Specified in Its Charter) Kiryat Hadassah Minrav Building ? Fifth Floor Jerusalem, Israel (Address o |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 Commission file number: 001-38556 ENTERA BIO LTD. (Exact Name of Registrant as Specified in Its Charter) Kiryat Hadassah Minrav Building ? Fifth Floor Jerusalem, Israel (Address o |
|
| November 10, 2021 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT?S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management?s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommended that you read this in conjunction with our unaudited condensed consolidated financial statements for the nine -month period ended Sept |
|
| November 10, 2021 |
Exhibit 99.1 Entera Bio Reports Third Quarter 2021 Financial Results ? Two Presentations at ASBMR, including Late Breaker, on Phase 2 EB613 Clinical Trial Results in Osteoporosis ? ? Study Sets Stage for Phase 3 registrational trial in 2022 ? BOSTON, Massachusetts & JERUSALEM, Israel ?November 10, 2022 ? Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule |
|
| October 28, 2021 |
Exhibit 99.1 Entera Bio Publishes Key Study Describing its Oral Delivery Technology Platform for Biologic Drugs ?Study describes a dual mechanism of action approach to oral drug delivery of large molecules, the ?Holy Grail? of drug development. ?Technology is utilized in Entera?s EB613 oral PTH drug for osteoporosis and several other molecules now in development by Entera and in collaboration with |
|
| October 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2021 Commission file number: 001-38556 ENTERA BIO LTD. (Exact Name of Registrant as Specified in Its Charter) Kiryat Hadassah Minrav Building ? Fifth Floor Jerusalem, Israel (Address of |
|
| October 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2021 Commission file number: 001- 38556 ENTERA BIO LTD. (Translation of registrant's name into English) Kiryat Hadassah Minrav Building ? Fifth Floor Jerusalem, Israel (Address of princ |
|
| October 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2021 Commission file number: 001-38556 ENTERA BIO LTD. (Exact Name of Registrant as Specified in Its Charter) Kiryat Hadassah Minrav Building ? Fifth Floor Jerusalem, Israel (Address of |
|
| October 6, 2021 |
Exhibit 99.1 Entera Bio Presents Positive Phase 2 6-Month Bone Mineral Density Data for Oral PTH Formulation at Late Breaker ASBMR Conference Session Increases in lumbar spine, femoral neck and total hip BMD demonstrated with EB613 Linear Dose Responses Seen in Biomarker and Bone Mineral Density Data ? Pivotal Phase 3 registration study expected to commence 2022 BOSTON & JERUSALEM ? (October 6, 20 |
|
| September 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2021 Commission file number: 001-38556 ENTERA BIO LTD. (Exact Name of Registrant as Specified in Its Charter) Kiryat Hadassah Minrav Building ? Fifth Floor Jerusalem, Israel (Address |
|
| September 1, 2021 |
Exhibit 99.1 Entera Bio Selected for Late Breaking Oral Presentation of Phase 2 6-Month Osteoporosis Data at ASBMR 2021 Annual Meeting ? Second of Two Presentations to be Delivered by Entera ? ? Final 6-Month Bone Mineral Density (BMD) Results Show Dose-Related Efficacy ? BOSTON, Massachusetts & JERUSALEM, Israel ? September 1, 2021 ? Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of |
|
| August 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2021 Commission file number: 001-38556 ENTERA BIO LTD. (Exact Name of Registrant as Specified in Its Charter) Kiryat Hadassah Minrav Building - Fifth Floor Jerusalem, Israel (Address of |
|
| August 27, 2021 |
Exhibit 99.1 ENTERA BIO LTD. Kiryat Hadassah Minrav Building - Fifth Floor Jerusalem, Israel August 26, 2021 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MONDAY, OCTOBER 4, 2021 Dear Shareholders: We cordially invite you to attend the annual general meeting of shareholders, or the Meeting, of Entera Bio Ltd., or the Company, to be held at 5:00 p.m. (Israel time) on Monday, Octobe |
|
| August 27, 2021 |
Exhibit 99.2 ENTERA BIO LTD. PROXY CARD FOR ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MONDAY, OCTOBER 4, 2021 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned hereby appoints Dr. Jamas Spiros and Ms. Dana Yaacov-Garbeli as the true and lawful attorneys, agents and proxies of the undersigned, with full power of substitution to each of them, to represent and to |
|
| August 23, 2021 |
Entera Bio to Conduct Annual Shareholders Meeting on October 4, 2021 Exhibit 99.1 Entera Bio to Conduct Annual Shareholders Meeting on October 4, 2021 BOSTON, Massachusetts & JERUSALEM, Israel ? August 23, 2021 ? Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced it will host its annual shareholders meeting on Monday, October 4, 2021. About Entera Bio Entera is a leader in the development of |
|
| August 23, 2021 |
Entera Bio to Present at H.C. Wainwright 23rd Annual Global Investment Conference EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Exhibit 99.1 Entera Bio to Present at H.C. Wainwright 23rd Annual Global Investment Conference BOSTON, Massachusetts & JERUSALEM, Israel – August 23, 2021 – Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the Company’s CEO Spiros Jamas will present at the H.C. Wainwright 23rd Annual |
|
| August 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2021 Commission file number: 001-38556 ENTERA BIO LTD. (Exact Name of Registrant as Specified in Its Charter) Kiryat Hadassah Minrav Building ? Fifth Floor Jerusalem, Israel (Address of |
|
| August 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2021 Commission file number: 001-38556 ENTERA BIO LTD. (Exact Name of Registrant as Specified in Its Charter) Kiryat Hadassah Minrav Building ? Fifth Floor Jerusalem, Israel (Address of |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2021 Commission file number: 001-38556 ENTERA BIO LTD. (Exact Name of Registrant as Specified in Its Charter) Kiryat Hadassah Minrav Building ? Fifth Floor Jerusalem, Israel (Address of |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2021 Commission file number: 001-38556 ENTERA BIO LTD. (Exact Name of Registrant as Specified in Its Charter) Kiryat Hadassah Minrav Building ? Fifth Floor Jerusalem, Israel (Address of |
|
| August 16, 2021 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT?S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management?s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommended that you read this in conjunction with our unaudited condensed consolidated financial statements for the six-month period ended June 3 |
|
| August 16, 2021 |
EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Exhibit 99.1 Entera Bio Reports Second Quarter 2021 Financial Results and Provides Clinical Updates ‒ Phase 2 EB613 Clinical Trial in Osteoporosis Achieves 6-month Bone Mineral Density Endpoint; Primary and Key Secondary Endpoints Met ‒ ‒ Preparing for End of Phase 2 Meeting with FDA for Planned Pivotal One-year Phase 3 Study Comparing Changes in Lumbar Spine |
|
| August 16, 2021 |
Exhibit 99.1 ENTERA BIO LTD. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) AS OF JUNE 30, 2021 ENTERA BIO LTD. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) AS OF JUNE 30, 2021 TABLE OF CONTENTS Page CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) - U.S DOLLARS IN THOUSANDS ($): Condensed consolidated statements of financial position F-2 Condensed consol |
|
| August 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2021 Commission file number: 001-38556 ENTERA BIO LTD. (Exact Name of Registrant as Specified in Its Charter) Kiryat Hadassah Minrav Building ? Fifth Floor Jerusalem, Israel (Address of |
|
| August 2, 2021 |
EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Exhibit 99.1 Entera Bio to Present Phase 2 EB613 Oral PTH Osteoporosis Treatment 3- Month Findings at the American Society for Bone and Mineral Research Annual Meeting ‒ The Study’s Primary Endpoint was Met; P1NP, a Biochemical Marker of Bone Formation, was Significantly Increased at Month 3 in EB613 2.5 mg Treatment Group Versus Placebo ‒ ‒ Full 3-Month Bioc |
|
| June 30, 2021 |
ENTX / Entera Bio Ltd / RA CAPITAL MANAGEMENT, L.P. - ENTERA BIO LTD. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Entera Bio Ltd. (Name of Issuer) Ordinary Shares Nominal value of NIS 0.0000769 per share (Title of Class of Securities) M40527109 (CUSIP Number) June 23, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| June 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2021 Commission file number: 001-38556 ENTERA BIO LTD. (Exact Name of Registrant as Specified in Its Charter) Kiryat Hadassah Minrav Building ? Fifth Floor Jerusalem, Israel (Address of pr |
|
| June 23, 2021 |
EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Exhibit 99.1 ENTERA BIO ANNOUNCES EXCELLENT TOPLINE PHASE 2 BMD DATA FOR EB613, THE STUDY MET ITS PRIMARY AND KEY SECONDARY ENDPOINTS - Subjects receiving the 2.5 mg dose of EB613 showed significant dose-related increases in BMD at the lumbar spine, total hip, and femoral neck at 6 months - Subjects receiving the 2.5 mg dose of EB613 for 6 months had a signif |
|
| June 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2021 Commission file number: 001-38556 ENTERA BIO LTD. (Exact Name of Registrant as Specified in Its Charter) Kiryat Hadassah Minrav Building ? Fifth Floor Jerusalem, Israel (Address of pr |
|
| June 22, 2021 |
EX-99 3 exhibit5-1.htm EXHIBIT 5.1 Exhibit 5.1 May 7, 2021 To: Entera Bio Ltd. Kiryat Hadassah, Minrav Building - Fifth Floor Jerusalem Israel Re: Prospectus Supplement Ladies and Gentlemen: We have acted as Israeli counsel to Entera Bio Ltd., an Israeli company (the “Company”) in connection with the At Market Sales Issuance Agreement, dated as of May 7, 2021 (the “Sales Agreement”), entered into |
|
| June 22, 2021 |
EX-99 2 exhibit1-1.htm EXHIBIT 1.1 Exhibit 1.1 Execution Version ENTERA BIO LTD. Ordinary Shares (par value NIS 0.0000769 per share) At Market Issuance Sales Agreement May 7, 2021 B. Riley Securities, Inc. 299 Park Avenue, 21st Floor New York, NY 10171 Ladies and Gentlemen: Entera Bio Ltd., an Israeli company (the “Company”), confirms its agreement (this “Agreement”) with B. Riley Securities, Inc. |
|
| June 17, 2021 |
EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Exhibit 99.1 Entera Bio Receives Foundational Patent for its Oral PTH using its Platform Oral Protein Delivery Technology in European Union ‒ Oral delivery technology has potential to transform $20 billion injectable biologics market ‒ - Final BMD results from company’s Phase 2 Osteoporosis study of EB 613 expected in Q2/2021 BOSTON, Massachusetts & JERUSALEM |
|
| June 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2021 Commission file number: 001-38556 ENTERA BIO LTD. (Exact Name of Registrant as Specified in Its Charter) Kiryat Hadassah Minrav Building ? Fifth Floor Jerusalem, Israel (Address of pr |
|
| June 14, 2021 |
ENTX / Entera Bio Ltd / Knoll Capital Management, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. 1)* Entera Bio Ltd. (Name of Issuer) Ordinary Shares Nominal value of NIS 0.0000769 per share (Title of Class of Securities) M40527109 (CUSIP Nu |
|
| May 20, 2021 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT?S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This management?s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommended that you read this in conjunction with our unaudited condensed consolidated financial statements for the three-month period ended Marc |
|
| May 20, 2021 |
Exhibit 99.1 ENTERA BIO LTD. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) AS OF MARCH 31, 2021 ENTERA BIO LTD. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED) AS OF MARCH 31, 2021 TABLE OF CONTENTS Page CONDENSED CONSOLIDTED FINANCIAL STATEMENTS (Unaudited) - U.S DOLLARS IN THOUSANDS ($): Condensed consolidated statements of financial position 2 Condensed consoli |
|
| May 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2021 Commission file number: 001-38556 ENTERA BIO LTD. (Exact Name of Registrant as Specified in Its Charter) Kiryat Hadassah Minrav Building ? Fifth Floor Jerusalem, Israel (Address of pri |
|
| May 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2021 Commission file number: 001-38556 ENTERA BIO LTD. (Exact Name of Registrant as Specified in Its Charter) Kiryat Hadassah Minrav Building ? Fifth Floor Jerusalem, Israel (Address of pri |
|
| May 20, 2021 |
EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Exhibit 99.1 Entera Bio Reports First Quarter 2021 Financial Results and Provides Clinical Updates ‒ Phase 2 EB613 Clinical Trial in Osteoporosis Achieves 3-Month Primary Endpoint; Final Data Including BMD Expected Q2:21 ‒ ‒ Entera’s Oral Delivery Platform Shows Potential in Indications Including GLP-2 and Human Growth Hormone ‒ ‒ Company to Host Conference C |
|
| May 7, 2021 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-239843 Prospectus Supplement (to Prospectus dated July 22, 2020) 5,000,000 Ordinary Shares We have entered into a Sales Agreement with B. Riley Securities, Inc., or B. Riley Securities, dated May 7, 2021, relating to the sale of our ordinary shares offered by this prospectus supplement. In accordance with the terms of the Sales Agreement, under |
|
| May 7, 2021 |
Sales Agreement, dated as of May 7, 2021 between Entera Bio Ltd. and B. Riley Securities, Inc Exhibit 1.2 ENTERA BIO LTD. Ordinary Shares (par value NIS 0.0000769 per share) At Market Issuance Sales Agreement May 7, 2021 B. Riley Securities, Inc. 299 Park Avenue, 21st Floor New York, NY 10171 Ladies and Gentlemen: Entera Bio Ltd., an Israeli company (the ?Company?), confirms its agreement (this ?Agreement?) with B. Riley Securities, Inc. (the ?Agent?) as follows: 1. Issuance and Sale of Sh |
|
| April 20, 2021 |
Entera Announces Ron Mayron, a Global Pharma Leader, Joins its Board of Directors EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Exhibit 99.1 Entera Announces Ron Mayron, a Global Pharma Leader, Joins its Board of Directors BOSTON, Massachusetts & JERUSALEM, Israel (April 20, 2021) – Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced that Ron Mayron has joined its Board of Directors. Mr. Mayron is taking the seat |
|
| April 20, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2021 Commission file number: 001-38556 ENTERA BIO LTD. (Exact Name of Registrant as Specified in Its Charter) Kiryat Hadassah Minrav Building ? Fifth Floor Jerusalem, Israel (Address of p |
|
| April 15, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2021 Commission file number: 001-38556 ENTERA BIO LTD. (Exact Name of Registrant as Specified in Its Charter) Kiryat Hadassah Minrav Building ? Fifth Floor Jerusalem, Israel (Address of p |
|
| April 15, 2021 |
ENTERA APPOINTS RAMESH RATAN AS CHIEF FINANCIAL OFFICER Exhibit 99.1 ENTERA APPOINTS RAMESH RATAN AS CHIEF FINANCIAL OFFICER BOSTON, Massachusetts & JERUSALEM, Israel (April 15, 2021) ? Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the appointment of veteran finance and operations executive Ramesh Ratan as U.S. Chief Financial Officer. Mr. Ratan replaces Jonathan Lieber who |
|
| April 6, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2021 Commission file number: 001-38556 ENTERA BIO LTD. (Exact Name of Registrant as Specified in Its Charter) Kiryat Hadassah Minrav Building ? Fifth Floor Jerusalem, Israel (Address of p |
|
| April 6, 2021 |
Exhibit 99.1 New Data Suggest Entera?s Platform Orally Delivers Human Growth Hormone, Study Results to be Presented at European Pharma Congress BOSTON, Massachusetts & JERUSALEM, Israel (April 6, 2021) ? Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the Company will deliver a poster presentation titled ?Pharmacokinetics |
|
| March 18, 2021 |
EX-1.1 2 exhibit1-1.htm EXHIBIT 1.1 Exhibit 1.1 ARTICLES OF ASSOCIATION OF ENTERA BIO LTD. A COMPANY LIMITED BY SHARES UNDER THE COMPANIES LAW, 5759–1999 1. INTERPRETATION 1.1. In these Articles, unless the context requires otherwise, the following capitalized terms shall have the meanings set opposite them: “Alternate Nominee” has the meaning set out in Article 17.7; “Alternate Director” has the |
|
| March 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| March 18, 2021 |
EX-2.2 3 exhibit2-2.htm EXHIBIT 2.2 Exhibit 2.2 Description of Securities The following is a summary of the material terms of our securities registered under Section 12 of the Securities Exchange Act of 1934 (the “Exchange Act”). All references to the “Company,” “we,” “us,” “our” and “Entera” refer to Entera Bio Ltd. As of December 31, 2020, our Ordinary Shares, par value NIS 0.0000769 per share ( |
|
| March 18, 2021 |
Certification pursuant to section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 12.1 CERTIFICATION TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Dr. Spiros Jamas, certify that: 1. I have reviewed this annual report on Form 20-F of Entera Bio Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such stat |
|
| March 18, 2021 |
EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Exhibit 99.1 ENTERA BIO LTD ANNOUNCES OPERATING AND FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2020 ‒ Achieved Primary Endpoint in EB613 Phase 2 Clinical Trial ‒ ‒ Final Data, Including Bone Mineral Density, Expected in Q2:21 ‒ ‒ FDA Approval of EB613 IND for the Treatment of Osteoporosis Enables Initial U.S. Clinical Trial ‒ ‒ Amgen |
|
| March 18, 2021 |
Exhibit 4.30 November 30, 2020 Re: Offer of Employment Dear Spiros Jamas, I am very pleased to confirm our offer to you of employment with Entera Bio, Inc. (the ?Company?), a wholly owned subsidiary of Entera Bio Ltd., an Israeli Company (the ?Parent?), as the Chief Executive Officer of Parent (the ?Position?). You will report to the board of directors of the Parent (the ?Parent Board?). We are ea |
|
| March 18, 2021 |
Exhibit 13.1 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with the Annual Report on Form 20-F of Entera Bio Ltd. (the “Company”) for the fiscal year ended December 31, 2020 (the “Report”), I, Spiros Jamas, certify pursuant t |
|
| March 18, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2021 Commission file number: 001-38556 ENTERA BIO LTD. (Exact Name of Registrant as Specified in Its Charter) Kiryat Hadassah Minrav Building ? Fifth Floor Jerusalem, Israel (Address of p |
|
| March 18, 2021 |
Exhibit 13.2 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with the Annual Report on Form 20-F of Entera Bio Ltd. (the “Company”) for the fiscal year ended December 31, 2020 (the “Report”), I, Jonathan Lieber, certify pursuan |
|
| March 18, 2021 |
Certification pursuant to section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 12.2 CERTIFICATION TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Jonathan Lieber, certify that: 1. I have reviewed this annual report on Form 20-F of Entera Bio Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such state |
